Posterior reversible encephalopathy syndrome in childhood hematological/oncological diseases: Multicenter resulte

dc.contributor.authorBilir, Özlem Arman
dc.contributor.authorDikme, Gürcan
dc.contributor.authorMalbora, Barış
dc.contributor.authorSivis, Zühal Önder
dc.contributor.authorTüfekçi, Özlem
dc.contributor.authorBahadır, Ayşenur
dc.contributor.authorKaraman, Serap
dc.contributor.authorVural, Sema
dc.contributor.authorBayhan, Turan
dc.contributor.authorYaralı, Hüsniye Neşe
dc.contributor.authorÇelkan, Tülin Tiraje
dc.contributor.authorÖzbek, Namık Yaşar
dc.contributor.buuauthorEvim, Melike Sezgin
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji ve Onkoloji Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-1452-2021tr_TR
dc.contributor.scopusid36337796600tr_TR
dc.date.accessioned2024-01-22T07:58:14Z
dc.date.available2024-01-22T07:58:14Z
dc.date.issued2021-05
dc.description.abstractThe aim of the study was to analyze the characteristics of posterior reversible encephalopathy syndrome (PRES) cases treated at 10 different institutions in our country. Fifty-eight patients diagnosed with PRES were included in this study. The data of PRES cases from 10 departments of pediatric hematology/oncology were analyzed. The mean age of the patients at the time of diagnosis of PRES was 8.95±3.66 years. Most patients (80.4%) had a primary diagnosis of acute leukemia. Patients received chemotherapy (71.4%) and/or used steroids within 14 days before the diagnosis of PRES (85.7%). Hypertension was found in 83.9% of the patients. Twenty-six patients had infections and 22 of them had febrile neutropenia. The most common electrolyte disorders were hypocalcemia, hypomagnesemia, and hypopotassemia. Six patients had tumor lysis syndrome and 4 had inappropriate antidiuretic hormone syndrome. Magnetic resonance imaging was used for diagnosis in all patients. The most commonly involved regions by magnetic resonance imaging were occipital (58%), parietal (51%), and frontal lobes (45%), respectively. Twenty-five patients required intensive care and 7 patients were intubated. In conclusion, PRES may develop during the follow-up and treatment of hematological diseases. In addition to steroid and intense combined chemotherapies, immunosuppressive agents and hypertension are also factors that may be responsible for PRES.en_US
dc.identifier.citationBilir, Ö. A. vd. (2021). "Posterior reversible encephalopathy syndrome in childhood hematological/oncological diseases: Multicenter resulte". Journal of Pediatric Hematology/Oncology, 43(4), E462-E465.en_US
dc.identifier.doihttps://doi.org/10.1097/MPH.0000000000001965
dc.identifier.eissn1536-3678
dc.identifier.endpageE465tr_TR
dc.identifier.issn1077-4114
dc.identifier.issue4tr_TR
dc.identifier.pubmed33060391tr_TR
dc.identifier.scopus2-s2.0-85105548823tr_TR
dc.identifier.startpageE462tr_TR
dc.identifier.urihttps://journals.lww.com/jpho-online/fulltext/2021/05000/posterior_reversible_encephalopathy_syndrome_in.10.aspx
dc.identifier.urihttps://hdl.handle.net/11452/39209
dc.identifier.volume42tr_TR
dc.identifier.wos000647760900010
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalJournal of Pedıatrıc Hematology Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChilden_US
dc.subjectPresen_US
dc.subjectEncephalopathyen_US
dc.subjectHematologic diseaseen_US
dc.subjectHypertensionen_US
dc.subjectNervous-system complicationsen_US
dc.subjectAcute lymphoblastic-leukemiaen_US
dc.subjectChildrenen_US
dc.subjectLeukoencephalopathyen_US
dc.subjectManifestationsen_US
dc.subjectChemotherapyen_US
dc.subjectHematopoietic stem-cellen_US
dc.subjectOncologyen_US
dc.subjectHematologyen_US
dc.subjectPediatricsen_US
dc.subject.emtreeAnticonvulsive agenten_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeCyclosporineen_US
dc.subject.emtreeMycophenolate mofetilen_US
dc.subject.emtreeSteroiden_US
dc.subject.emtreeAcute ieukemiaen_US
dc.subject.emtreeAcute iymphoblastic leukemiaen_US
dc.subject.emtreeAcute myeloid leukemiaen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAplastic anemiaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAtaxia telangiectasiaen_US
dc.subject.emtreeB cell ieukemiaen_US
dc.subject.emtreeBurkitt ieukemiaen_US
dc.subject.emtreeBurkitt ieukemiaen_US
dc.subject.emtreeBurkitt iymphomaen_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeCancer combination chemotherapyen_US
dc.subject.emtreeCancer diagnosisen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeChildhood canceren_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeCongenital amegakaryocytic thrombocytopeniaen_US
dc.subject.emtreeDisease predispositionen_US
dc.subject.emtreeEndotracheal intubationen_US
dc.subject.emtreeEpilepsyen_US
dc.subject.emtreeFebrile neutropeniaen_US
dc.subject.emtreeFrontal lobeen_US
dc.subject.emtreeHematologic malignancyen_US
dc.subject.emtreeHematologyen_US
dc.subject.emtreeHemophagocytic syndromeen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHypertensionen_US
dc.subject.emtreeHypocalcemiaen_US
dc.subject.emtreeHypokalemiaen_US
dc.subject.emtreeHypomagnesemiaen_US
dc.subject.emtreeInappropriate vasopressin secretionen_US
dc.subject.emtreeInfectionen_US
dc.subject.emtreeIntensive careen_US
dc.subject.emtreeLeukemiaen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMulticenter study (topic)en_US
dc.subject.emtreeNuclear magnetic resonance imagingen_US
dc.subject.emtreeOccipital lobeen_US
dc.subject.emtreeOncologyen_US
dc.subject.emtreeParietal lobeen_US
dc.subject.emtreePediatric warden_US
dc.subject.emtreePosterior reversible encephalopathy syndromeen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeT cell leukemiaen_US
dc.subject.emtreeThalassemia majoren_US
dc.subject.emtreeTumor lysis syndromeen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeComplicationen_US
dc.subject.emtreeDiagnostic imagingen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHematologic diseaseen_US
dc.subject.emtreeLeukemiaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMetabolic disorderen_US
dc.subject.emtreeMulticenter studyen_US
dc.subject.emtreePosterior reversible encephalopathy syndromeen_US
dc.subject.meshAdolescenten_US
dc.subject.meshChilden_US
dc.subject.meshFemaleen_US
dc.subject.meshHematologic diseasesen_US
dc.subject.meshHumansen_US
dc.subject.meshHypertensionen_US
dc.subject.meshLeukemiaen_US
dc.subject.meshMagneticen_US
dc.subject.meshResonance imagingen_US
dc.subject.meshMaleen_US
dc.subject.meshPosterior leukoencephalopathy syndromeen_US
dc.subject.meshWater-electrolyte imbalanceen_US
dc.subject.scopusPosterior Reversible Encephalopathy Syndrome; Case Report; Hypertension Encephalopathyen_US
dc.subject.wosOncologyen_US
dc.subject.wosHematologyen_US
dc.subject.wosPediatricsen_US
dc.titlePosterior reversible encephalopathy syndrome in childhood hematological/oncological diseases: Multicenter resulteen_US
dc.typeArticleen_US
dc.wos.quartileQ4en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections